[PDF][PDF] 非小细胞肺癌靶向治疗研究进展
苗秋丽， 张四喜， 王红玉， 王红 - 医药导报, 2017 - yydbzz.com
… of chemotherapy and erlotinib for patients with advanced stagenon-small-celllungcancer(FASTACT-2):a …
Phase Ⅱ study of bevacizumab and erlotinib in the treatment of advanced …
Phase Ⅱ study of bevacizumab and erlotinib in the treatment of advanced …
[HTML][HTML] 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展
张国伟， 王慧娟， 张米娜， 李鹏… - Chinese Journal of Lung …, 2015 - ncbi.nlm.nih.gov
… in chemotherapy, we pointed out that the future of traditional chemotherapy must be part of
"… SELECT: a multicenter phase Ⅱ trial of adjuvant erlotinib in resected early-stage EGFR …
"… SELECT: a multicenter phase Ⅱ trial of adjuvant erlotinib in resected early-stage EGFR …
轻量型网片和重量型网片应用于Lichtenstein 腹股沟疝修补术长期疗效的Meta 分析
燕东， 王权， 薛芙珍， 孙学强， 刘登瑞， 王丽艳， 牛强龙… - 循证医学, 2014 - jebm.cn
… Final results of OPTIMOX2, a large randomized phase Ⅱ study of maintenance therapy or
chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (…
chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (…
HER2 阳性转移性乳腺癌治疗年度进展
柴洁， 姚和瑞 - 岭南现代临床外科, 2018 - lingnanwaike.com
… 该研究中的化疗方案有两类,其中曲妥珠单抗联 合蒽环类化疗的安全性分析显示患者心脏毒性
明 显增加,AC 方案联合靶向时心衰发生率达到 27%.因此在和曲妥珠单抗联合配伍时,常规蒽 …
明 显增加,AC 方案联合靶向时心衰发生率达到 27%.因此在和曲妥珠单抗联合配伍时,常规蒽 …
宫颈癌分子靶向治疗的研究进展
杨莉， 程玺 - 中国癌症杂志, 2015 - china-oncology.com
… phase Ⅱ study of bevacizumab in combination with definitive radiotherapy and cisplatin
chemotherapy … A phase Ⅱ trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a …
chemotherapy … A phase Ⅱ trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a …
[PDF][PDF] 吉非替尼联合GP 化疗方案治疗晚期非小细胞肺癌的效果及对血清CEA, SCC, NSE, CYFRA21-1 水平的影响
任宝恒， 万伟， 周庆元， 宋利明… - Progress in Modern …, 2019 - biomed.cnjournals.com
… A phase II open-label multicenter study of gefitinib in … followed by chemotherapy in patients
with inoperable stage III non-… A phase III randomised controlled trial of erlotinib vs gefitinib in …
with inoperable stage III non-… A phase III randomised controlled trial of erlotinib vs gefitinib in …
吡柔比星巩固治疗急性早幼粒细胞白血病疗效研究
冯佳， 柳金， 庞丽萍， 温娟娟， 钟凤鸾， 张倩， 孟庆祥 - 中国肿瘤临床, 2012 - cjco.cn
… 2 Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for …
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J]. Lancet …
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J]. Lancet …
[HTML][HTML] PD⁃ 1/PD⁃ L1 免疫检查点抑制剂在肺癌临床研究中的进展
王梦玮， 徐天蔚， 王朝霞 - 南京医科大学学报(自然科学版), 2021 - jnmu.njmu.edu.cn
… Nivolumab versus docetaxel in a predominantly Chinese patient population with previously
treated advanced NSCLC:CheckMate 078 randomized phase Ⅲ clinical trial[J].J Thorac On…
treated advanced NSCLC:CheckMate 078 randomized phase Ⅲ clinical trial[J].J Thorac On…
[HTML][HTML] 中国埃克替尼治疗非小细胞肺癌专家共识（ 2016 年版）
石远凯， 孙燕， 丁翠敏， 王子平， 王长利… - Chinese Journal of …, 2016 - ncbi.nlm.nih.gov
… LUX-Lung6: A randomized, open label, phase Ⅲ study of afatinib (A) versus gemcitabine/cisplatin
(GC) as first line treatment for Asian patients with EGFR mutation positive advanced …
(GC) as first line treatment for Asian patients with EGFR mutation positive advanced …
[HTML][HTML] 胶质母细胞瘤对替莫唑胺耐药机制的研究进展
李盈盈， 冯黎黎， 韩峰 - 南京医科大学学报(自然科学版), 2024 - jnmu.njmu.edu.cn
… NRG oncolo⁃ gy/RTOG1205:a randomized phase Ⅱ trial of concurrent bevacizumab and
reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma[J].J Clin Oncol,…
reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma[J].J Clin Oncol,…